Faster and safer safety cabinet fumigation
Hydrogen peroxide system offers alternative to toxic formaldehyde fumigation of safety cabinets
An easier and faster alternative to formaldehyde fumigation, the Skanair DECOSIS is a mobile unit used directly in the lab, and connected to the safety cabinet via two tubes. It functions autonomously thanks to a control system and catalytic converter.
Because it uses hydrogen peroxide (H2O2) as a biocide, decomposition products are unproblematic, and maintenance work can subsequently be safely carried out on the decontaminated cabinet.
The unit can be used to decontaminate microbiological safety cabinets in advance of maintenance work, when changing job or location, in preparation for disposal, or in the event of breakdowns or accidents.
It can also be used to decontaminate incubators, air locks and small isolators.
The cabinet continues to run in reduced mode throughout the procedure. The trained maintenance technician enters the corresponding facility parameters at a control system display, together with the quantity of H2O2 defined on the basis of the Skanair DECOSIS validation.
The process starts at the touch of a button, and runs completely automatically: the internal ventilation unit maintains slight negative pressure and feeds H2O2 vapour through the front cover into the cabinet, continuously circulating it inside the cabinet to reach all contaminated areas. The exhaust air through the cabinet‘s HEPA filter is then fed back into the Skanair DECOSIS via the second tube to be recirculated.
The decontamination phase is followed by the flushing phase: any biocides in the exhaust air from the cabinet are removed inside the Skanair DECOSIS via a catalytic converter and a final HEPA filter. This air can then be released directly into the lab, without having to be extracted via the building exhaust air system.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results